Q&A with Jim Vaughan of 3M Drug Delivery Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Jim Vaughan of 3M Drug Delivery Systems

Pharmaceutical Technology
Volume 34, Issue 2, pp. 70


Jim Vaughan

PharmTech: Do you see a new industry trend emerging?

Vaughan: New developments in the Asia–Pacific region have been interesting to follow. In 2009, for the first time, most of the world’s bioscience degrees were awarded to people outside the United States, and we are certainly seeing the changes that is bringing about. The explosion of startups, particularly in Asia, is one of the key factors in our expansion of laboratory facilities. Our new laboratory in Singapore supports earlystage product development and late-stage regulatory data demands, so we are able to serve new and established pharmaceutical companies in that region. We expect this laboratory to become a major research hub, in addition to our research locations in the US and United Kingdom. An additional trend is the expansion of microneedle technology, in which we are seeing increased interest. At 3M, we have long experience with this technology and we feel well positioned, with our solid and hollow, microstructured transdermal systems, to meet the new demands for these applications.

PharmTech: What is the most common demand your clients are currently making of you?

Vaughan: Our clients are looking for innovation in drug delivery and new ways to administer their products. Our chief technologies are in the areas of inhalation and transdermal delivery, so we are often called upon to adapt drug products to these methods. The capabilities of both technologies are expanding, and the inhalation market is growing to include larger molecules than before, including proteins and peptides. Inhalation is a promising delivery route for local and systemic drug delivery. The number of transdermal therapies is growing steadily as well. We have created a method of solid microneedle delivery that expands the range of medications that can be delivered transdermally to patients, including vaccines, proteins, and peptides. We also are working on a hollow, microstructured transdermal system that will further expand the range of medications for which transdermal systems can be used.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here